Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302
February 01, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...
Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics
January 18, 2022 09:15 ET
|
Qualigen Therapeutics, Inc.
Preclinical Therapeutic Program to Be Initially Focused on Pancreatic Cancer CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology...
Qualigen Therapeutics Promotes Amy Broidrick to President
December 14, 2021 09:18 ET
|
Qualigen Therapeutics, Inc.
Ms. Broidrick to retain title of Chief Strategy Officer CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on...
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
December 01, 2021 15:25 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with certain...
QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERING
November 29, 2021 15:50 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing novel therapeutic products for the treatment of cancer,...
Qualigen Therapeutics, Inc. Reports Third Quarter 2021 Financial Results
November 15, 2021 09:00 ET
|
Qualigen Therapeutics, Inc.
Quarterly revenues increased 38% to approximately $1.2 million, compared to approximately $0.8 million in the same quarter of the previous yearYear-to-date revenues increased 30% to $4.2 million,...
Peer-Reviewed Article Confirms That Qualigen’s FastPack® is as Accurate in Thyroid Stimulating Hormone Measurement -- and Much Faster -- Than a Leading Laboratory Method
October 19, 2021 09:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 15, 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...
Qualigen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 07:30 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with...
Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results
August 17, 2021 08:00 ET
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif.,, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces its intention to prioritize its focus to its oncology pipeline that includes QN-247...